The Effect of Chimeric Antigen Receptor (CAR)-T Cell Therapy on the Reconstitution of HIV-specific Immune Function
Key facts
- Where
- Guangzhou, ChinaSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Where in China
- Guangzhou 8th People's HospitalGuangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Guangzhou 8th People's Hospital
- Trial code
- NCT03240328
- Record updated
- 14 September 2022
- Original description
To study the safety and effectiveness of CAR-T Cell therapy on HIV patients whose plasma HIV has been successfully suppressed after cART, which is expected to enhance the res-constitution of HIV-specific immune function to assist the eradication of HIV reservoir.Read full original descriptionShow less
The Effect of CAR-T Cell Therapy on the Reconstitution of HIV-specific Immune Function
To study the safety and effectiveness of CAR-T Cell therapy on HIV patients whose plasma HIV has been successfully suppressed after cART, which is expected to enhance the res-constitution of HIV-specific immune function to assist the eradication of HIV reservoir.
Inclusion: HIV infection confirmed; Receiving cART more than 12 months; HIV viral-load < 50 copies/ml and CD4 cell count more than 350 cells/ul; Without serious liver, heart, liver and kidney diseases; The subjects know about the study and volunteer to attend the research and sign the informed consent.
Exclusion: With active HBV or HCV infection, or serious opportunistic infections; With serious chronic disease such like diabetes, the mental illness,et al; History of suffering from pancreatitis during cART; Pregnant or breast-fed; With poor adherence; Unable to complete follow up.